Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts.

ABSTRACT:

Introduction

Subjective cognitive decline (SCD) in amyloid-positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.

Methods

Eight hundred twenty-one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed-effects models.

Results

In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive d

SUBMITTER: Shao K 

PROVIDER: S-EPMC11497667 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature